Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients with Cancer
- Ureteral stent in place at study registration
- Patient reports pain, spasms, or urgency symptoms after stent placement, which are thought to be unrelated to other causes as per the patient or healthcare provider or both (documentation in the medical record is unnecessary)
- Ability to complete English language questionnaires by themselves or with assistance
- Willingness to provide mandatory 24 hour urine collection samples for research purposes
- Able to swallow supplements
- Registration >= 3 days after placement of a new stent or >= 1 days after a stent exchange
- Willingness to refrain from grapefruit juice for 7 days prior to and for 7 days during the study
- Receiving warfarin at registration
- Active cholecystitis
- Taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin, irinotecan); buspirone, benzodiazepines, zolpidem, calcium channel blockers (such as felodipine, nifedipine, verapamil); digoxin or quinidine; codeine or fentanyl; phenytoin, propranolol, rifampin, or theophylline
- History of alcohol abuse
I. To conduct a dose-escalation study with curcumin and piperine to derive a safe, optimal biological dose of this combination in cancer patients.
I. To describe the grade 2+ toxicities associated with curcumin and piperine.
II. To evaluate quality of life associated with this combination by means of the Mayo Modified Urinary Stent Symptom Questionnaire (USSQ).
I. To characterize the change in urinary prostaglandin E2 concentrations that occur at baseline and then after one week of curcumin + piperine.
OUTLINE: This is a dose-escalation study of curcumin.
Patients receive curcumin orally (PO) twice daily (BID) or thrice daily (TID) and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month.
Trial Phase Phase I
Trial Type Supportive care
- Primary ID MC1511
- Secondary IDs NCI-2015-01716
- Clinicaltrials.gov ID NCT02598726